Evidence map›Paper›PMID 28130042›Full record

ArticleAmerican journal of ophthalmology2017

Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.

Rupin N Parikh, Anastasia Traband, Anton M Kolomeyer, Brian L VanderBeek, Benjamin J Kim, Albert M Maguire, Alexander J Brucker

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage.International journal of retina and vitreous · 2020
    Review
  9. Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy.International journal of molecular sciences · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rupin N ParikhScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania; Albany Medical College, Albany, New York.
Anastasia TrabandScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Anton M KolomeyerScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Brian L VanderBeekScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Leonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Benjamin J KimScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Albert M MaguireScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Alexander J BruckerScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: ajbrucke@mail.med.upenn.edu.
Penn Presbyterian Medical Center · US

Funding

Patient Centered Care for Diabetic Macular EdemaK23EY025729 · NEI · UNIVERSITY OF PENNSYLVANIA · PI VANDERBEEK, BRIAN L. · 2015 to 2019
$1.1M
NEI NIH HHS K23 EY025729NEI NIH HHS L30 EY023819
6 · The paper itself

Abstract

purposeTo evaluate the outcomes of intravitreal bevacizumab (IVB) use in patients with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

designRetrospective, interventional case series.

methodsPatients who presented to Scheie Eye Institute between January 2008 and January 2015 with a new VH secondary to PDR and treated with IVB were included. Exclusion criteria consisted of IVB treatment prior to the study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up. Outcomes of interest were additional treatments including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year.

resultsOf the 111 eligible eyes, 55 (49.5%) had PRP, 35 (31.6%) were managed with injections alone, and 21 (18.9%) had PPV after 1 year. The overall average number of injections during this time was 2 (range, 1-9), and 13 (11.7%) eyes were managed with a single injection alone. Of the 69 eyes with 2 years of follow-up, 43 (62.3%) had PRP, 16 (23.2%) were treated with injections alone, and 10 (14.5%) had PPV.

conclusionsThis study underscores the potentially important role that IVB injections have in the management of patients with VH secondary to PDR. The results indicate that a proportion of patients may be treated with a minimal amount of intervention requiring 1 or 2 anti-vascular endothelial growth factor injections only. Also, the rate of PPV at 2 years (27.9%, n = 31) suggests that most patients may be managed nonsurgically.

Indexed as

Visual AcuityAngiogenesis InhibitorsBevacizumabDiabetic RetinopathyDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedRetrospective StudiesTreatment OutcomeVitreoretinopathy, ProliferativeVitreous HemorrhageAngiogenesis InhibitorsBevacizumab

Identifiers

PMID28130042
PMCPMC5376507
OpenAlexW2582945869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.